Krajina: Izrael
Jazyk: angličtina
Zdroj: Ministry of Health
DEFERASIROX
TARO INTERNATIONAL LTD, ISRAEL
V03AC03
DISPERSIBLE TABLETS FOR ORAL SUSPENSION
DEFERASIROX 125 MG
PER OS
Required
SUN PHARMACEUTICAL INDUSTRIES LTD, INDIA
DEFERASIROX
Deferasirox Taro is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over). Deferasirox Taro is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. Chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [LIC]≥5 mg Fe/g dry weight [dw] or serum ferritin consistently >800 μg/l). LIC is the preferred method of iron overload determination and should be used wherever available.
2022-12-22
Patient leaflet in accordance with the Pharmacists' Regulations (Preparations) - 1986 The medicine is dispensed with a doctor’s prescription only DEFERASIROX TARO ® 125 mg Dispersible tablets for oral suspension DEFERASIROX TARO ® 250 mg Dispersible tablets for oral suspension DEFERASIROX TARO ® 500 mg Dispersible tablets for oral suspension Each dispersible tablet contains: deferasirox 125 mg Each dispersible tablet contains: deferasirox 250 mg Each dispersible tablet contains: deferasirox 500 mg Inactive ingredients and allergens in this medicine: see section 2 under ‘Important information about some of this medicine’s ingredients’, and section 6 ‘Additional information'. Read the entire leaflet carefully before you start using this medicine. This leaflet contains concise information about this medicine. If you have any further questions, consult your doctor or pharmacist. This medicine has been prescribed to treat your or your child's illness. Do not pass it on to others. It may harm them, even if it seems to you that their illness is similar to yours. 1. WHAT IS THIS MEDICINE INTENDED FOR? • To treat chronic iron overload caused by blood transfusions(transfusional hemosiderosis) in adults and children (aged 2 years and older). • To treat chronic iron overload in patients with non-transfusion- dependent thalassemia aged 10 years and older. Therapeutic group: iron chelating agent. Repeated blood transfusions are sometimes necessary in patients suffering from certain types of anemia such as thalassemia, sickle-cell disease and myelodysplastic syndromes (MDS). However, repeated blood transfusions may cause a build-up of excess iron. This is because blood contains iron and the body does not have a natural way to remove the excess iron received with the blood transfusions. In patients with non-transfusion-dependent thalassemia, iron overload may develop over time, mainly due to increased absorption of dietary iron in response to low blood cell counts. Over time, the excess iron can damage vital org Prečítajte si celý dokument